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Abstract 
Opioids are important in the management of pain in patients with cancer. Clinicians and patients are 
sometimes concerned about the effect of opioids on survival, which might decrease opioid 
prescription, compliance and symptom control. We wanted to determine whether opioid analgesia 
was associated with shorter survival in adult patients with cancer. We systematically searched for 
studies that assessed the effect of regular systemic opioid analgesia on survival. We identified 526 
unique records, with 20 articles meeting inclusion criteria. Thirteen end-of-life studies, including 11 
very low quality retrospective studies, did not find a consistent association between opioid analgesic 
treatment and survival, this evidence comes from low quality studies, so should be interpreted with 
caution. Seven longer-term studies, including 3 randomised controlled trials and 2 prospective 
studies were included. Six of these studies indicated that opioids were likely to be associated with a 
shorter survival. None of these studies were powered to assess the effect of opioids on survival as a 
primary endpoint. In view of this, no definitive conclusions can be made as to whether opioids affect 
survival in cancer patients. These data suggest that while opioid analgesia does not affect survival at 
the end of life, in the context of longer-term treatment, higher quality studies, with survival as a 
primary endpoint, are needed to confirm an independent association between opioid analgesia and 
shorter survival. An important limitation of research in this field is that the relationship between 
greater analgesic requirements and shorter survival may be mediated by painful progressive cancer. 
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INTRODUCTION 
Opioids are commonly used for pain management in patients with cancer [1,2]. There are 
international guidelines based on systematic review data for the use of opioids for cancer pain [3], 
however over 30% of patients remain undertreated [4]. As well as having beneficial effects, opioids 
have a range of adverse effects. These include constipation, emesis, cognitive dysfunction and 
addiction, as well as more recent concerns about effects on immune function, cancer growth and 
even their impact on survival [5-9]. Unwanted drug effects are a major concern for clinicians, 
patients and carers and affect opioid prescription and compliance which limit their use and 
potentially increase suffering caused by pain [4,7-14].  
Opioids could potentially affect survival by having acute or chronic effects. Although there are 
differences between opioids, acute effects are primarily on respiratory drive (this is unlikely a major 
issue in appropriately used long term opioids in patients with cancer) or on the cardiac QTc interval 
causing torsades de pointes [15,16]. Opioids could potentially be associated with a longer survival 
due to improvements in pain, as higher pain scores in patients with cancer are associated with a 
shorter survival [17-20]. The chronic effects of opioids on survival could include effects on cancer 
growth which might be mediated by direct effects of opioids on host cells (including angiogenesis or 
actions on immune cells) or cancer cells (including cancer cell development, apoptosis and 
metastasis) [21-25], Figure 1. Opioids can inhibit components of both innate and adaptive immunity 
[21,22,26,27], although a recent systematic review of non-surgical patients with cancer did not find 
any studies which correlated immune function to clinical outcomes (e.g. cancer progression, 
recurrence and survival) [28]. In patients with advanced cancer, the systemic inflammatory response 
and cachexia decrease survival; opioids, via immune and endocrine effects, might influence cancer 
progression/recurrence and survival, although the overall effect of morphine on these outcomes in 
clinical practice is poorly understood [28-31]. 
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These effects have been explored in preclinical models using morphine as the archetypical opioid, 
although there are differences between opioids [15,27]. The effect of intraoperative opioids in 
patients undergoing cancer surgery has been reviewed elsewhere [32-35]. Several long term 
retrospective studies have shown a benefit of the opioid-sparing effect of regional or spinal 
analgesia, alongside general anaesthesia, on cancer recurrence or survival in the resection of breast, 
prostate and colon tumours [36-38]. However other retrospective studies have not shown these 
benefits in prostate, colorectal, and cervical cancers even though there was a reduced need for 
postoperative opioids [39-41]. In surgery for early lung cancer, intraoperative opioids were 
associated with shorter survival, which was not the case in later stage disease [42]. A prospective 
multicentre randomised trial in abdominal cancer resection showed no effect of postoperative 
systemic opioids in cancer recurrence and mortality [43]. Previous reviews of opioids on survival 
have only included patients with advanced cancer and a short prognosis [44,45]. How regular 
systemic opioid analgesia impacts on survival in non-surgical patients with cancer is currently 
unknown [28], therefore this remains an important research question. 
 
METHODS  
Search strategy  
We wanted to determine whether regular systemic opioid analgesia in adult patients with cancer 
was associated with shorter survival compared to adult patients with cancer not treated with regular 
systemic opioid therapy or treated with a lower dose of systemic opioids.  We aimed to include 
previous reviews on opioids at the end of life, and expand upon them by including studies which 
examined the association between regular systemic opioid analgesia and survival in patients not at 
the end of life. This systematic review followed an a priori protocol according to the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [46]. The review 
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protocol was registered on the PROSPERO website (http://www.crd.york.ac.uk/PROSPERO) before 
screening and data extraction (registration no. CRD42014013261) [47].  
In  August 2014 we searched the electronic databases Embase Classic+Embase (Ovid) 1947+; Ovid 
MEDLINE(R) 1946+; Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations; Conference 
Proceedings Citation Index -Science 1990+ (Web Of Science, Thomson Reuters); ClinicalTrials.gov 
(U.S. NIH); International Clinical Trials Registry Platform (WHO); CINAHL 1981+ (EbscoHost); 
Cochrane Database of Systematic Reviews (Wiley): Issue 7 of 12, 2014; Database of Abstracts of 
Reviews of Effect (Wiley): Issue 2 of 4, 2014; Cochrane Central Register of Controlled Trials (Wiley): 
Issue 6 of 12, 2014; and NHS Economic Evaluation Database (Wiley): Issue 2 of 4, 2014. Search 
strategies were devised to be inclusive of all potentially relevant studies using both Medical Subject 
Heading (MeSH) terms and text word searches to increase the search sensitivity. Terms for ‘opioids’, 
‘cancer’ and ‘survival’ were combined to identify relevant studies. The search terms for opioids 
included individual drug names and generic terms ‘opioids’ and ‘opiate’. The cancer search included 
the MeSH term ‘exp neoplasms/’ and text word searches for synonyms for cancer. The ‘survival’ 
search included terms and synonyms for life expectancy, mortality and time to death. Search 
strategies from all databases are available on request from the authors. 
In addition to the electronic search, reference lists from identified publications were manually 
searched, as were previous reviews on opioids and survival and searches of the authors’ own files. 
Experts in the field were consulted to ensure that no articles were missed. Unpublished studies were 
also included in the search. When only a conference abstract was available and the full study was 
unpublished, authors were contacted to try to ascertain further information. Searches were not 
restricted to English.  
 
Inclusion, exclusion and selection criteria 
6 
 
Inclusion criteria: assessed the effect of opioids on survival of adult, human, patients with cancer (or 
predominantly cancer patients). Study types: randomised controlled trials, cohort studies, 
prospective and retrospective observational studies, database analysis. 
Exclusion criteria: surgery (e.g. opioids for perioperative pain), opioids taken recreationally, opioids 
used for addiction. Study types: case studies.  
Studies conducted in patients undergoing cancer surgery, healthy volunteers or animals were 
excluded from this systematic review as these groups have different opioid usage (duration, 
administration schedule and opioid type) and receptor expression compared to patients on long-
term opioids for cancer pain [32,33,48-50]. Patients undergoing surgery are also exposed to a range 
of drugs during the operation which potentially impact on survival [32,33].  
Two authors (JB and LZ) independently reviewed all titles and abstracts in order to assess their 
relevance for inclusion. Full text papers were retrieved for those fulfilling the criteria, and also for 
those publications for which the ability to assess their eligibility could not be assessed on the basis of 
the titles and abstracts alone. These authors then assessed the full texts of all potentially relevant 
studies. Disagreement at all stages was resolved by consensus and with recourse to a third review 
author (EB). The results of these searches are shown in the PRISMA Flow Diagram (Figure 2) [46]. 
 
Data extraction, assessment and analysis  
JB and LZ independently extracted data regarding study design and results and assessed their 
quality. Data extracted included the type of study, study setting, study population (cancer type, 
stage, treatment) opioid used and dose, statistical analysis used and clinical outcome measures (e.g. 
survival). The methodological quality of each study was independently assessed by JB and LZ using 
the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system 
[51,52]. 
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RESULTS 
Studies included 
We identified 526 unique records of which 20 studies were included in this systematic review (Figure 
2 and Table 1). Due to the heterogeneous nature of these studies (in study design, duration/dose of 
opioid administered, measurement of survival) a meta-analysis was not possible and a narrative 
analysis has been performed. The studies were either in patients in the last days to weeks of life or 
in patients with months or years left to live. They were thus subdivided into studies assessing people 
in the last month of their life and those studies which were performed in patients with a longer 
prognosis (more than one month). The studies which assessed the effect of regular systemic opioid 
analgesia in patients at the end of life were generally low in quality using the GRADE system. This 
was principally due to their retrospective nature, and none were randomised controlled trials  [53]. 
Studies assessing people with a longer prognosis tended to be of higher quality; these were mostly 
RCTs and prospective observation studies.  
 
End of life studies: 
Study characteristics 
There were 13 studies which evaluated the effect of regular systemic opioid analgesia on survival in 
patients with cancer who were in the last days or weeks of life. Using the GRADE criteria, 11 of these 
were of a very low and 2 were of a low quality (Table 1). There were 11 retrospective studies and 2 
represented a secondary data analysis (Table 1). The mean sample size was 254 patients. By their 
nature, these studies generally had a short follow-up, over days to a short number of weeks, 
sometimes just measuring opioid use in the last days of life. They were generally based in a 
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hospice/palliative care setting with a heterogeneous population with patients having a variety of 
cancer types. These studies tended to show that the opioid dose increased during hospice admission 
or with specialist palliative care input [54-57]. However, a large increase in the opioid dose did not 
generally occur in the last 2 days of life [54,55]. The time at which the opioid dose was reported was 
variable: including at baseline [17], measured daily [58], in the last 24h [53] or 48h [59] of life. The 
comparator varied between studies and included opioids vs no systemic opioids and high vs low 
dose opioids. 
 
Effect of opioids on survival 
The outcome of these studies differed. Some of the studies indicated a potential association of 
increased survival with higher doses of opioids or increases in opioid dose in the last days of life 
[53,55,60,61]. Others report no relationship between survival and overall dose or change in opioid 
dose [57-59,62,63]. In other studies, higher opioid dose or increasing doses of opioids were reported 
to be associated with a shorter survival (Table 1) [19,56,64].  
From these studies, in mixed patient groups and settings, there is no clear association between 
opioid dose or increasing doses of opioids and survival; with some indicating that opioids might be 
associated with a decreased survival, and other studies suggesting that opioids improve survival, or 
have no effect. The appropriate use of higher opioid doses is emphasised [58] and many studies are 
based in a hospice, Hospital at Home Unit or in a specialist palliative care setting, which might have a 
skewed population as these patients probably represent a group of complex pain syndromes 
[19,53,61]. These studies can only look for an association between opioids and survival as there is no 
truly matched comparison to evaluate causality [53]. 
 
Long term studies: 
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Study characteristics 
There are 7 studies which evaluated the effect of regular systemic opioid analgesia on survival in 
patients with cancer not undergoing surgery that lived for months to years. Using the GRADE 
criteria, 3 studies were moderate, 3 were low quality and 1 was very low quality (Table 1). There 
were 3 RCTs, 3 prospective studies and 1 retrospective study (Table 1). These studies tended to be 
multicentre (Table 1) [18,29,65,66]. The mean sample size was 485 patients. These studies included 
patients with diverse cancers as outlined in Table 1, but principally included patients with advanced 
cancers, with some studies having a relatively homogenous population [29,65,67]. The comparator 
varied between studies and included opioids vs no systemic opioids and high vs low dose opioids. 
 
Effect of opioids on survival 
All 3 RCTs, 2 of the 3 prospective studies and the retrospective study described a potential 
association between strong systemic opioid use or increasing dose and shorter survival. One RCT 
reported a non-significant trend for shorter survival in patients treated with oral opioids compared 
with intrathecal opioids for pain control (6 month survival 37% vs. 54%; p=0·06) [66]. Although the 
intrathecal group had a larger OME dose than the medically managed group, systemically the opioid 
concentration would be orders of magnitude less. Pain control was better and less opioid toxicity 
was reported in the intrathecal group which might have contributed to the potential survival benefit 
[66,68]. Another RCT evaluated opioid use on endocrine function and survival (survival was not the 
primary outcome), despite the median OME being low (females 40mg and males 80 mg/d), survival 
was shorter (median 78 days) in opioid-using male patients compared with non-opioid-users 
(median 132 days; p=0·009) [29]. Furthermore, in males opioid dose was highly correlated to low 
testosterone, and hypogonadal males had a shorter survival compared to those who were 
eugonadal [29]. In developing a prognostic model in chemotherapy for patients with advanced 
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prostate cancer, a secondary data analysis from 2 large chemotherapy RCTs showed that opioid use 
was independently associated with a shorter survival (Hazard Ratio [HR] 1·09) [65]. Importantly this 
study had a single time based assessment of yes/no opioid use without following the patients or 
looking at doses. In a conference abstract based on this data (n=836), there was a relationship 
between shorter survival and opioid at baseline and at 3 months, with a shorter survival if opioids 
were used both at baseline and at 3 months (median survival 18 months, compared with 27 months 
for patients not on opioids at baseline or 3 months; p<0·001), although dose relationships were not 
explored [69].  
In 2 of the 3 prospective studies, opioids were associated with a shorter survival [18,70]. Prescription 
of opioids stronger than tramadol was independently associated with a shorter survival (HR 2·5; 
p=0·001), although only baseline opioid was reported with small numbers on opioids [18]. Strong 
opioids significantly decreased median survival in a haematological study (from a median survival of 
191 days without opioids to 27 days with strong opioids; p<0·0001) [70]. A longitudinal observational 
study showed no effect of opioids on survival up to 1 year, although the numbers were very small 
with only 21 people out of the cohort of 64 having died by 1 year, they also did not report the actual 
number of people in each group or how many had died [17]. In the retrospective study, increased 
opioid requirement after diagnosis was associated with a shorter progression free survival (HR 1·08; 
p<0·001) and shorter overall survival (HR 1.07; p<0·001), but was not associated with time to 
progression (as measured by prostate specific antigen), although this was associated with opioid 
requirement prior to diagnosis (HR 1·23; p=0·002). Furthermore, for every 5mg/d increase in opioid 
requirement after diagnosis, the risk of death increased by 5% [67]. Finally, in this cohort, high levels 
of mu opioid receptors in the prostate cancer cells were associated with increased cancer 
progression and a shorter survival [67]. 
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Several studies in different groups of patients with cancer have indicated that prolonged exposure to 
regular systemic opioid analgesia might be associated with a shorter survival; this seemed 
particularly evident with strong opioids (Table 1).  
 
Limitations of the included studies 
Many of the included studies had significant limitations; these are outlined in table 1 under the 
column confounders/limitations. These included limitations in the study design (mostly retrospective 
for end of life studies), as well as in the population, intervention, comparator and outcome 
measures. 
Patient population:  Some studies used discrete population with a very limited life expectancy such 
as hospice admission. Different baseline characteristics, such as those receiving higher doses of 
regular systemic opioid analgesia were more likely to be younger and male, there were also 
differences between types of cancer [19,55,60-63,66,70], with a minority of non-cancer patients 
included in some studies [19,57].   
Intervention: The starting point for opioid use, the duration of opioid administration or when data 
was recorded differed between studies. Some studies only report the opioid dose at death or at 
baseline giving a cross-sectional view, not the overall accumulative opioid dose or how this changes. 
Morphine was the principal opioid in most studies and the different opioids used were pooled which 
although increased the number of participants in each group, removed the ability to explore any 
potential differences in effect on survival between opioids (however, it is useful to have an 
approximate equivalence between the different opioids as OME, which standardised opioid dose). 
There tended to be small numbers of patients on higher dose opioids [19,55,60,62,63]. In some 
studies, patients were only on opioids for pain [71], in other studies opioids were also used for 
different (or multiple) indications, such as sedation, dyspnea and cough [54,55,57,64]. In studies, 
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using a change of opioid dose, it is often unclear why the dose was changed; especially when it was 
decreased (e.g. was the patient sleepy or confused, and what the cause of this was) [58]. 
Comparison: In general the control groups were not directly matched, i.e. not patients who suffered 
from refractory severe symptoms but did not choose opioids. The comparison was not consistent 
between studies. This included patients who received an increase in opioids at the end of life with 
those who received no/little increase [54,61], or between patients on high doses of opioids vs lower 
doses [17] or no opioid [29,65,70]. The high dose opioid threshold varied between studies but was 
generally an OME dose above 120 - 300mg/d, although up to 600mg/d in one study [17,19,59,61]. 
Other studies used weak vs strong opioids [18,70]. Portenoy et al, reported that an OME above 
60mg/d was equally associated with a shorter survival compared with below 51mg/d [19], this leads 
to the possibility that some other studies might miss an effect as they did not compare to a low 
enough dose. However, other studies showed the survival cut off to be at higher doses: Median 
survival 7d for OME<120 mg/d, 8d for OME 120–299 mg and 16d for OME>300 mg [53]. Many other 
drugs (including other analgesics and sedatives) were also used and often not precisely reported 
[53,57].  
Outcome: The time point from which survival was measured varied, these included: from admission 
[54]; from maximum administered dose of opioids to death and dose escalation [19,61]; from last 
opioid dose change [19], or a designated time frame, such as 1 year [17]. In some studies survival 
was not a study end point or formed part of a secondary data analysis [19,63,65,66]. Some of these 
studies used multiple methods of measuring survival and generally only 1 analysis method showed 
association with survival [19,61]. Furthermore, not knowing what the patients’ estimated prognosis 
was before starting on or having a dose escalation of opioid makes it hard to compare outcomes 
between groups. 
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DISCUSSION 
This is the first systematic review to examine the association between regular systemic opioid 
analgesia and survival in all non-surgical patients with cancer. We found no clear relationship 
between opioid analgesia and survival in patients at the end of life, with days or weeks to live, this 
evidence comes from low quality studies, so should be interpreted with caution. However we found 
that in six out of the seven longer-term studies, opioid analgesia was (or had a tendency to be) 
associated with a shorter survival, although these studies did not have survival as a primary, 
appropriately powered, endpoint. In view of this we cannot make any definitive conclusions with 
regards to whether opioids affect survival in cancer patients. The data suggest that if opioids have an 
effect, this takes weeks to months to impact on survival (longer than the survival time of end-of-life 
patients), and therefore the chronic effects of opioids are more likely to be important than acute 
effects (Figure 1). Our findings are important because oncological therapy is improving and cancer 
patients are living longer. There is now a growing group of cancer survivors who often have long-
term treatment-related effects such as pain which might be managed with long term opioids. 
However, there were a number of confounding factors and limitations in the design of many of the 
studies, all of which were of low to moderate quality.  
Pain caused by cancer can be due to multiple mechanisms, involving numerous mediators (e.g. 
cytokines, nerve growth factor and endothelin-1) as well as peripheral and central neuro-immune 
interactions [72-74]. Cancer cells and activated immune cells can secrete endogenous opioids which 
interact with nociceptors [72,74]. Prescribed opioids produce pain relief principally by activating mu 
opioid receptors and by opening inwardly rectifying potassium channels; opioids also have 
downstream effects on intracellular messengers including the activation of phospholipase C, protein 
kinase C, mitogen-activated protein kinase and Nuclear Factor-B. [72,75-79]. 
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Confounding factors 
Survival is a multifactorial phenomenon influenced by complex factors, many of which might not be 
measurable [18,19,57]. The effect of opioids on survival is dependent on many other factors, 
including the effect of opioids on pain, and effect of pain on survival as well as the interaction 
between opioids, pain, wellbeing, emotional distress and depression [17]. Poor performance status, 
pain and strong opioids were associated with the a shorter survival [18], however in other studies 
those on higher dose opioids [63] or with escalated doses [61] had a better performance status. 
Higher pain scores in patients with cancer are associated with a shorter survival [17-20]. There is 
likely a triangulated relationship between opioids, pain and survival (as outlined in figure 1). It might 
be that in the studies where higher opioid doses are associated with a longer survival, that pain is 
better controlled and that these would have otherwise adversely impacted on survival [53,59-61]. 
Increasing pain from cancer, and thus higher opioid doses, could be related to more advanced 
disease which in itself will shorten survival [57,71]. At end of life, when the patient was unable to 
swallow, it is possible that analgesics only availably orally were stopped, thus necessitating a higher 
dose of parenteral opioids to control pain. In some studies a lower opioid dose on admission 
increased survival, however this effect was lost following adjustment for other clinical factors, 
suggesting that the indication for the opioid may explain the survival differences [58].  
 
Opioids other than morphine 
Most of the studies have been done with morphine or pooling all opioids together irrespective of 
their differing effects [27], this leaves very little scope to determine if there is a difference between 
opioids, e.g. is it a group effect of all opioids or a morphine effect. Van Hooft and colleagues showed 
that taking opioids stronger than tramadol was an independent (taking pain into account) prognostic 
factor for short survival [18]. This might relate to patients being on weaker opioids having less 
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advanced disease. There was one study where controlled release oxycodone was assessed, the dose 
of this was not associated with survival at the end of life, although there was a trend for moderate 
oxycodone doses (OME 62-300 mg/d) to be associated with the longest survival and high doses 
(OME >300 mg/d) to be associated with the shortest survival [63]. 
 
Limitations of this review 
The main limitation of this systematic review was that the results could not be pooled due to study 
heterogeneity. There were also methodological issues with many of the studies included, which 
were generally of a low quality. It is also possible that we have omitted relevant studies despite our 
detailed search strategy. In terms of the comparison of high vs. low opioids (or patients needing 
more of an increase in opioids) these are being used for symptom control and thus those patients 
needing more opioids might have worse symptoms or at least need a higher dose to control them. 
More advanced disease might mean increased levels of pain, necessitating higher doses of opioids. 
Furthermore in many studies the final symptom levels are not reported and it is unlikely all patients 
will have attained the same level of symptom control. There were marked inconsistences between 
the patients included, the interventions, comparators and outcomes. Often there were many 
outcome measures or calculations used in the studies. Generally the opioids were converted to OME 
doses, it was unclear if they were they all converted in the same way between studies. 
 
Future work 
Future work needs to employ a robust methodology, either using large data sets or prospective 
cohorts to answer specific questions in a predefined way (although this will only show an 
association) or RCTs with survival as a primary endpoint to demonstrate causality. A placebo RCT 
design cannot be conducted in this situation as it is not ethical to withhold accepted, proven 
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analgesics which form the basis for pain guidelines globally. To randomise against another opioid 
would be possible, although this might not show a difference as we do not have the available data to 
know if this is potentially a class or individual opioid effect.  
 
Conclusions  
This systematic review has revealed that although there have been many studies assessing the 
effects of regular systemic opioid analgesia on survival, these tend to be of a low quality or survival is 
not the primary outcome. Despite the low quality and methodological difficulties, the end-of-life 
studies do not suggest a clear association of opioid use and survival. In view that they are low quality 
studies, this should be interpreted with caution. The longer term studies, which are generally of a 
higher quality, potentially indicate that regular systemic opioid analgesia is likely to be associated 
with a shorter survival, although these did not examine the effect of opioid on survival as a primary 
endpoint. In view of this, no definitive conclusions can be made with regard to whether opioids 
affect survival in cancer patients.  Furthermore the differences between opioids have not been 
adequately explored to inform if opioid choice is relevant. Currently, based on available data, opioids 
should continue to be used for pain control in patients with cancer. An important limitation of 
research in this field is that the relationship between greater analgesic requirements and shorter 
survival may be mediated by painful progressive cancer. 
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Figures  
Figure 1: Potential mechanisms by which opioids might impact on survival in patients with cancer. 
During acute administration high doses of some opioids might inhibit respiratory drive and shorter 
survival. Certain opioids have been shown to prolong the heart’s QTc interval causing torsades de 
pointes. Chronic effects of opioids on cancer include apoptosis, angiogenesis and immunity. It is also 
possible that these immune effects might be offset as opioids decrease pain which itself might be 
immunosuppressive. Opioids might also have direct effects on the cancer cells. [16,21,28,67,80] 
 
  
24 
 
Figure 2: Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2009 
flow diagram [46]. 
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Table 1 – Effect of opioids on survival in patients with cancer. 
Study Research 
question / 
Aim 
Study 
design 
Patient 
population / 
setting 
Intervention  Comparator Outcome  Confounders/ 
limitations 
Study 
quality 
(GRADE 
criteria) 
End of life studies        
(Bercovitch, 
Waller et al. 1999) 
High dose 
morphine use in 
the hospice 
setting. A 
database survey 
of patient 
characteristics 
and effect on life 
expectancy [62]. 
What are the 
characteristics of 
patients requiring 
high dose 
morphine and the 
effect on survival? 
Retrospective 
review 
453 patients 
(from 651; 70%) 
on morphine with 
mixed cancers 
admitted to a 
hospice in Israel 
 
 
 
High dose 
opioids (299-599 
mg/d OME): 19 
patients (4%). 
Very high dose 
opioids >599 
mg/d OME: 36 
patients (8%) 
Low dose opioids 
(<299 mg/d 
OME):  
398 patients 
(88%) 
 
 
 
No statistical 
difference in 
survival time 
between opioid 
doses. Mean 
survival time: 
very high dose 
13d;  
high dose 15d;  
low dose 14d 
Retrospective  
Mixed cancers 
Opioids pooled 
Short term follow-up 
– from hospice 
admission. 
Small number of 
patients on high 
doses 
 
Very Low 
(Thorns and 
Sykes 2000) 
Opioid use in last 
week of life and 
implications for 
end-of-life 
decision-making  
[54]. 
 
 
Is symptom 
control with 
opioids associated 
with shortening of 
life in palliative 
care? 
Retrospective 
review 
 
 
 
 
Of 238 
consecutive 
patients dying in 
a UK hospice,  
212 (89%) 
received opioids 
in the last 24 h of 
life 
Marked increase 
in opioid dose at 
the end of life 
28 patients 
(12%) 
No/small increase 
in opioid dose at 
the end of life 
210 patients 
(88%) 
No statistical 
difference in 
survival from 
hospice 
admission. 
Mean survival: 
21d for dose 
increase group  
vs. 16d for 
no/small 
increase group  
(p=0.7) 
Retrospective  
Mixed cancers 
Opioids pooled 
Small increase in 
the median daily 
opioid dose in the 
last week of life. 
Small numbers in 
dose increase 
group 
Very Low  
(Morita, Tsunoda 
et al. 2001) 
Effects of High 
Dose Opioids and 
Sedatives 
on Survival in 
Terminally Ill 
Cancer Patients 
[59]. 
Is opioid dose 
related to survival 
in last 2 days of 
life? 
Secondary 
analysis of a 
prospective 
observational 
study 
 
209 patients (172 
on opioids) with 
mixed cancers on 
a palliative care 
unit in Japan  
 
High dose 
opioids (>240mg 
OME/48h): 45 
patients (22%) 
 
No/Low dose 
opioids (<240mg 
OME/48h): 164 
patients (78%) 
No difference 
in survival time 
between opioid 
doses (p=0.23) 
Mixed cancers 
Opioids pooled 
Short term follow-
up. Small numbers 
of patients in higher 
dose opioid groups. 
Opioids only 
recorded in last 2 
days of life 
Low  
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(Bercovitch and 
Adunsky 2004) 
Patterns of high-
dose morphine 
use in a home-
care hospice 
service: should 
we be afraid of it? 
[60] 
 
What are the 
characteristics of 
patients on high 
dose morphine 
use (>299mg/d) 
and does it affect 
survival? 
Retrospective 
review  
435 outpatients 
(from 661; 66%) 
on morphine with 
mixed cancers 
treated by a 
home-care 
hospice team in 
Israel 
High dose 
opioids (>299 mg 
/d OME): 
39 patients (9%)  
Low dose opioids 
(5-299 mg /d 
OME): 
396 patients 
(91%) 
Higher opioid 
dose 
associated 
with longer 
median 
survival 
(P<0.001). 
Median 
survival: high 
dose 27d; low 
dose 18d;  
no opioids 22d 
 
Retrospective  
Mixed cancers 
(analysed by cancer 
type). 
Only used opioid 
dose at baseline. 
Short term follow-up 
from Palliative care 
admission. 
Small number of 
patients on higher 
dose opioids. 
Younger patients in 
higher dose opioid 
groups 
Very Low 
(Good, 
Ravenscroft et al. 
2005) 
Effects of opioids 
and sedatives on 
survival in an 
Australian 
inpatient palliative 
care population 
[53]. 
Does opioid and 
sedative 
medication use 
affect survival 
(from hospice 
admission to 
death) of patients 
in an Australian 
inpatient palliative 
care unit? 
Retrospective 
review  
229 patients (222 
on opioids) 
admitted to a 
palliative care unit 
High dose 
opioids (≥300 
mg/d OME) in 
the last 24 h of 
life: 63 patients 
(28%) 
 
No/low dose 
opioids (<300 
mg/d OME) in the 
last 24 h of life: 
166 patients 
(72%) 
Survival from 
hospice 
admission to 
death was 
longer in 
patients on 
≥300mg/d 
OME (p=0.01).  
Mean survival: 
high dose 18d;  
low dose 12d 
 
Retrospective  
Mixed cancers 
Opioids pooled 
Short term follow-up 
(from hospice 
admission to death), 
opioids recorded in 
the last 24h of life 
 
Very Low 
(Vitetta, Kenner et 
al. 2005) 
Sedation and 
analgesia-
prescribing 
patterns in 
terminally ill 
patients at the 
end of life [57]. 
 
Does sedation 
hasten death in 
terminally ill 
patients? 
 
Retrospective 
review 
 
102 consecutive 
patients who died 
during admission   
to an Australian 
hospice. 
92% cancer 
 
Patients on 
opioids at 
admission (mean 
dose 111 mg/d 
OME): 56 
patients (55%) 
Opioids only 
prescribed during 
the last week of 
life (mean dose at 
last week 69 mg/d 
OME): 36 patients 
(35%) 
Survival 
unrelated to 
opioid dose.  
Mean survival 
in patients 
taking opioids 
at admission: 
26d. 
Mean survival 
if opioids only 
prescribed 
during the last 
week of life: 
30d 
Retrospective  
Mixed cancers and 
8% non-cancer 
Opioids pooled 
Short term follow-up 
– from Palliative 
care admission 
(mean duration 26 
days). 
No comparison to 
patients not on 
opioids  
Very Low 
(Bercovitch and 
Adunsky 2006) 
To compare 
patients receiving 
Retrospective 
review 
97 consecutive 
patients with 
High dose 
OxyContin (>150 
Low dose 
OxyContin (0-30 
Survival was 
not related to 
Retrospective  
Mixed cancers  
Very Low 
27 
 
High dose 
controlled release 
oxycodone in 
hospice care [63]. 
high dose 
OxyContin with 
patients taking 
lower doses  
 terminal cancer 
admitted to a 
hospice in Israel 
(taking 
oxycodone as the 
only opioid) 
mg/d ~ 
>300mg/d OME): 
18 patients 
(19%) 
mg/d~ 0-60mg/d 
OME): 34 patients 
(35%) 
Moderate dose 
(31-150 mg/d ~ 
62-300mg/d 
OME): 45 patients 
(46%) 
OxyContin 
dose (p=0.12) 
Survival not primary 
outcome  
Short term (mean 
survival 12 days) 
 
(Portenoy, 
Sibirceva et al. 
2006) 
Opioid use and 
survival at the end 
of life: a survey of 
a hospice 
population [19]. 
Is survival after 
last opioid dose 
change 
associated with 
opioid dosing and 
other clinical 
characteristics? 
Secondary 
analysis of 
prospective 
longitudinal 
survey data  
725 patients with 
mixed cancer and 
non-cancer 
admitted to 13 
hospices in the 
USA who had at 
≥1 opioid dose 
change before 
death (from 1,306 
patients) 
 
42% cancer; 33% 
non-cancer; 25% 
both 
Patients on >200 
mg/d 
Intravenous 
morphine 
equivalent 
(IVME)  
(>600 mg/d 
OME): 85 
patients (11.7%) 
 
  
Patients on <200 
mg/d IVME  
(<600 mg/d 
OME): 640 
patients (88.3%) 
 
<17 mg/d  IVME 
(<51 mg/d OME): 
n=61 (8.4%) 
 
Shorter 
survival in 
patients on 
>20 mg/d 
IVME (>60 
mg/d OME) 
(p= 0.0001). 
Mean survival: 
27d for 
patients on 
<17 mg/d 
IVME vs. 12d 
for patients on 
20-25 IVME.  
 
Opioid dose 
accounted for 
6-8% of the 
overall effect 
on survival 
(depending on 
the analysis 
model) 
Mixed diseases, not 
just cancer 
Opioids pooled 
Study not designed 
to assess opioids 
and survival.  
Small numbers of 
patients in lowest 
and highest dose 
opioid groups. 
Larger proportion of 
cancer patients in 
higher dose opioid 
groups.  
Younger patients in 
higher dose opioid 
groups 
Low 
(Bengoechea, 
Gutierrez et al. 
2010) 
Opioid Use at the 
End of Life and 
Survival in a 
Hospital at Home 
Unit [61]. 
Do high doses of 
opioids, or 
increasing doses, 
influence survival 
in patients with 
terminal cancer 
who died in a 
Hospital at Home 
unit? 
Retrospective 
cohort study 
223 patients with 
mixed cancers 
admitted to the 
`Hospital at 
Home` unit in 
Spain 
 
High dose 
opioids 
(OME≥120 mg): 
99 patients 
(44%) 
 
(72% had 
previous opioids) 
Low dose opioids 
(OME<120 mg): 
124 patients 
(56%) 
 
(23% had 
previous opioids) 
No difference 
in adjusted 
survival 
between 
groups 
(p=0.34).  
Longer 
survival in 
patients who 
received 
opioids ≥ 
twofold higher 
Retrospective  
Mixed cancers 
Opioids pooled 
Short term follow-up 
– from `Hospital at 
Home` admission. 
Difference prior 
opioid exposure 
 
Very Low 
28 
 
than their initial 
doses during 
the last 7 days 
of life (22 vs. 9 
days) 
(p<0.0001) 
(Radha Krishna, 
Poulose et al. 
2010) 
Opioid Use 
amongst Cancer 
Patients at the 
End of Life [55]. 
Do opioids in the 
last 48 hours of 
life influence 
survival in 
terminally ill 
cancer patients? 
Retrospective 
review 
 
238 cancer 
patients referred 
to a hospital-
based specialist 
palliative care 
service in 
Singapore with 
terminal cancer 
and had died  
 
 
On opioids: 192 
patients (81%)  
 
24 hours before 
death 187 
patients (79%) 
on opioids, 
(median OME 57 
mg/d). 
 
48 hours before 
death 184 
patients (77%) 
on opioids. 
(median OME 48 
mg/d)  
No opioids:  
46 patients (19%) 
No difference 
between 
opioid/no 
opioid groups 
at 24h before 
death 
(P=0.69). 
Longer 
survival (from 
referral to 
palliative care) 
in patients who 
were on high 
doses of 
opioids at 24h 
before death 
(P=0.004)  
Retrospective  
Mixed cancers 
Opioids pooled 
Mixed indications 
for opioids 
Very small numbers 
of patients not on 
opioids or on higher 
dose/large increase 
opioid groups. 
Short term follow-up 
(median 5d) 
Opioid dose only 
recorded in last 48h 
of life 
Very Low 
(Da Costa 
Miranda, De 
Souza Fede et al. 
2011) 
Doctor, how long? 
[64] 
To quantify and 
identify variables 
influencing 
survival time in 
terminally sedated 
patients with 
cancer 
Retrospective 
cohort study 
181 consecutive 
patients with 
cancer who 
received terminal 
sedation in 
Brazil  
Opioids as single 
drug for 
sedation: 87 
patients (48%), 
with 128 (71%) 
needing a dose 
increase 
Other sedatives, 
multiple 
sedatives, no 
dose increase in 
opioids: 
94 patients (52%) 
Opioids as 
single sedative 
drugs or an 
increase in 
dose were 
associated 
with shorter 
survival, odds 
ratio 1.44 
(P=0.005)  
 
Retrospective  
Mixed cancers 
No info on opioid 
dose or by how 
much increased. 
Very short term 
follow-up (median 
survival 27 h)   
Mixed indications 
for opioids, 
including as 
sedative 
Very Low 
(Lin, Lin et al. 
2011) 
Symptom 
Patterns of 
Patients with 
Head and Neck 
Cancer in a 
Palliative Care 
To describe the 
symptom patterns 
of patients with 
terminal head and 
neck cancer in the 
palliative care unit 
Retrospective 
review 
94 patients who 
died of primary 
head and neck 
cancer admitted 
to a palliative 
care unit in China 
Opioid dose at 
death (median 
OME 160mg/d) 
Opioid dose on 
admission 
(median OME 
70mg/d) 
Change in 
morphine dose 
correlated with 
survival time 
after hospice 
admission 
(p<0.001) 
Retrospective  
Mixed cancers 
(although all head 
and neck) 
Opioids pooled  
Short follow-up 
(mean 22 days) 
 
Very Low 
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Unit [56]. 
(Azoulay, Jacobs 
et al. 2011) 
Opioids, Survival, 
and Advanced 
Cancer in the 
Hospice Setting 
[58]. 
Do opioids 
influence survival 
among advanced 
cancer patients 
following hospice 
admission? 
Retrospective 
observational 
study 
Data on 114 
consecutive 
hospice in-
patients (from 
117)  with 
advanced 
cancers in Israel 
 
OME >120 mg/d 
on admission: 32 
patients (28%)  
 
Last Day of Life: 
39 patients 
(34%) 
 
On admission: No 
opioids 29 
patients (25%),  
1–119 mg/d OME 
53 patients (47%)  
 
Last Day of Life: 
No opioids 9 
patients (8%) 
1–119 mg/d- 66 
patients (58%) 
From hospice 
admission, 
opioid dose 
had no effect 
on survival 
after 
adjustment for 
confounding 
factors 
Retrospective  
Mixed cancers 
Opioids pooled  
Short term follow-up 
– from Palliative 
care admission 
(mean 12 days) 
 
 
 
Very Low 
 
Studies in patients with a longer prognosis 
      
(Smith, Staats et 
al. 2002) 
Randomized 
Clinical Trial of an 
Implantable Drug 
Delivery System 
Compared With 
Comprehensive 
Medical 
Management for 
Refractory Cancer 
Pain: Impact on 
Pain, 
Drug-Related 
Toxicity, and 
Survival [66]. 
What is the effect 
of intrathecal vs. 
oral opioids on 
pain control and 
toxicity at 4 
weeks?  
 
Multicentre 
randomised 
controlled trial 
202 patients with 
mixed advanced 
cancers and 
refractory pain on 
at least 200mg 
OME in the USA 
(analysis on 148 
patients) 
 
 
Intrathecal 
opioids plus 
Comprehensive 
Medical 
Management: 
73 patients 
(49%) 
Oral opioids 
(Comprehensive 
Medical 
Management 
only): 75 patients 
(51%) 
Intrathecal 
group had 
trend (p=0.06) 
for increased 6 
month survival 
(54% vs. 37%) 
Mixed cancers 
Opioids pooled  
Survival was 
monitored but was 
not a study endpoint  
 
Moderate  
(O'Mahony, 
Goulet et al. 
2010) 
Psychosocial 
distress in 
patients treated 
for cancer pain: a 
prospective 
observational 
study [17]. 
Do opioids, 
depression, pain, 
wellbeing, desire 
for death, anxiety 
and PS impact on 
survival? 
Longitudinal 
Observational 
Study 
64 patients (52 
had opioids) with 
mixed cancers in 
the USA  
 
High dose 
morphine 
(>300mg/d) 
Number of 
people not 
reported   
Low  dose 
morphine 
(<300mg/d) 
Number of people 
not reported 
No difference 
between 
groups on 
survival to 1 
year 
 
 
Mixed cancers 
Opioids pooled  
Small numbers 
(actual number of 
people in each 
group was not 
reported) 
Only used opioid 
dose at baseline. 
Multiple outcomes. 
Very Low  
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Effect of opioids on 
survival not primary 
outcome measure 
(van Hooft, 
Dijkgraaf et al. 
2010) 
Independent 
predictors of 
survival in 
patients with 
incurable 
malignant gastric 
outlet obstruction: 
a multicenter 
prospective 
observational 
study [18]. 
 
Can baseline data 
in patients with 
incurable 
malignant gastric 
outlet obstruction 
(GOO) 
independently 
predict survival? 
Multicentre 
prospective 
observational 
study 
105 consecutive 
patients (Baseline 
data on 101) with  
malignant GOO 
treated with 
duodenal stent,  
in the 
Netherlands 
Opioids stronger 
than tramadol  
 
19 patients 
(19%) at 
Baseline 
No opioids/ 
opioids not 
stronger than 
tramadol 
 
82 patients (82%) 
at Baseline 
Opioids 
stronger than 
tramadol were 
associated 
with a shorter 
survival 
(Hazard Ratio 
2.5) (p=0.001)  
 
Mixed cancers 
Opioids pooled  
Only subdivided 
opioids into 
tramadol vs. 
stronger opioids  
small numbers of 
patients on strong 
opioids 
Only baseline opioid 
use reported 
 
Low   
(Skipworth, 
Moses et al. 
2011) 
Interaction of 
gonadal status 
with systemic 
inflammation and 
opioid use in 
determining 
nutritional status 
and prognosis in 
advanced 
pancreatic cancer 
[29]. 
Investigation into 
the interaction of 
gonadal status 
with systemic 
inflammation and 
opioids in 
determining 
nutritional status 
and prognosis in 
advanced 
pancreatic cancer 
A multicentre 
randomised 
trial 
167 patients 
(from 175 
randomised) with 
advanced 
pancreatic 
cancer; 43 
on opioids, in the 
USA 
Patients on 
opioids:  
Median OME 
dose females 
40mg males 80 
mg     
 
25 male (15%) 
18 female (11%) 
Patients not on 
opioids:  
 
65 male (39%)  
59 female (35%) 
Survival was 
shorter in male 
patients using 
opioid 
compared with 
non-opioid-
users; median 
78d vs 132d 
(p=0.009) 
  
Opioids pooled 
Small numbers of 
patients when 
subdivided into sex 
 
Moderate 
(Zylla, Gourley et 
al. 2013) 
Opioid 
Requirement, 
Opioid Receptor 
Expression, and 
Clinical Outcomes 
in Patients With 
Advanced 
Prostate Cancer 
[67]. 
What is the 
association of 
opioid dose on 
cancer 
progression and 
survival in 
patients with 
metastatic 
prostate cancer? 
Retrospective 
Observation 
Cohort 
analysis 
593 patients with 
stage IV prostate 
cancer 
In the USA (test 
cohort - 113 from 
Minneapolis VA 
Tumour Registry; 
validation cohort - 
480 patients from 
VA Central 
Cancer Registry)  
Average opioid 
dose (OME) for 1 
year before 
diagnosis and 
from diagnosis to 
death/last follow 
up  
Compared to 
other opioid 
doses 
Increased 
opioid 
requirement 
was 
associated 
with shorter 
survival 
(p<0.001) 
 
 
Retrospective 
Opioids pooled 
 
Low   
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(Halabi, Lin et al. 
2014) 
Updated 
Prognostic Model 
for Predicting 
Overall Survival 
in First-Line 
Chemotherapy for 
Patients With 
Metastatic 
Castration-
Resistant Prostate 
Cancer [65]. 
To develop a 
Model for 
Predicting Survival 
in Chemotherapy 
for Patients With 
Metastatic 
Castration-
Resistant Prostate 
Cancer 
Data from 2 
phase III 
RCTs 
(1050+942 
patients) 
1992 patients  
with metastatic 
castration-
resistant prostate 
cancer - data 
were split into 
training, testing 
and 
validation sets 
Patients on 
opioids:  
521 patients 
(29%) 
Patients not on 
opioids:  
1249 patients 
(71%) 
Opioid use 
was 
associated 
with a shorter 
survival 
(Hazard Ratio 
1.09)  
 
Secondary data 
analysis. 
Data for a specific 
patient group 
did not check dose 
effect 
Moderate 
(Kripp, Willer et al. 
2014) 
Patients with 
malignant 
hematological 
disorders treated 
on a palliative 
care unit: 
prognostic impact 
of clinical factors 
[70]. 
What are the 
potential 
prognostic clinical 
and laboratory 
factors in patients 
with 
haematological 
diseases admitted 
to a palliative care 
unit? 
 
Analysis of 
prospectively 
collected data 
from an 
observation 
Cohort 
290 consecutive 
patients (230; 
79% on opioids) 
with mixed 
haematological 
diseases 
admitted to a 
palliative care unit 
in Germany (from 
466 consecutive 
admissions) 
 
Patients on 
strong opioids:  
165 patients 
(72%) 
Patients not on 
strong opioids: 
125 patients 
(28%) 
Strong opioids 
associated 
with shorter 
survival; 
median 27d vs 
191d  
(p<0.0001) 
 
Single site, 
Haematological 
malignancies at 
different stages 
(small numbers for 
some diseases), 
opioids pooled - did 
not check dose 
effect. 
 
Patients admitted at 
different disease 
stages 
Low 
 
Abbreviations: OME - Oral Morphine Equivalents; IVME - Intravenous morphine equivalent; WHO – world health organisation; PS  - performance status; VA - Veterans 
Affairs;  
 
